Axplora Invests $60 Million in HPAPI Expansion at Farmabios Site in Italy
$60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy.
HPAPIs
HAS Acquires Cerbios-Pharma
HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).
Veranova Expands ADC and HPAPI Capabilities in the US
US contract development and manufacturing organization (CDMO) Veranova has initiated an expansion of its antibody-drug conjugate (ADC) and highly potent active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities at its US facility in Devens, Massachusetts.
Sterling Expands HPAPI Capabilities at US Facility
UK-headquartered contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has invested $3 million at its US facility in Germantown, WI, to expand the company’s integrated antibody-drug conjugate (ADC) development and manufacturing capabilities.
Olon to Open New High Potency API Suite in US
Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.
Axplora’s Farmabios Gets cGMP Approval for New Production Unit in Italy
Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for the first line of its new production unit at Gropello Cairoli, Italy, expanding its large scale manufacturing capabilities for high potent active pharmaceutical ingredients (HPAPIs) and steroids.
Containment Solutions for HPAPI Manufacturing
Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs now account for 25% of all drugs produced globally, with some analysts projecting that it will reach a value of $40 billion by 2027.
Lonza Completes HPAPI Expansion at Visp
Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding development and manufacturing capacity for ADC payloads.
Merck Germany Doubles HPAPI Potential
The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical ingredients (HPAPIs) at Verona, near Madison, Wisconsin to 6,500 m2.
Integrated Drug Development Models
Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.
Expansions in High-Potency API Manufacturing
DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.
Understanding the Requirements of Safe HPAPI Manufacturing
The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable targets for oncology and other areas.
The Rise of HPAPI Molecules
For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.
Francesca Scarpitta Joins Cerbios as Director of HPAI Manufacturing Units
Cerbios has appointed Francesca Scarpitta as director of the company’s high potency active ingredients (HPAIs) production units.
Cerbios Expands HPAI Manufacturing Capacity
Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in its building dedicated for high potency active ingredients (HPAIs).
Saltigo Realigns Strategy
Saltigo, the custom manufacturing business of Lanxess' Advanced Intermediates segment, which achieved total sales of €1.5 billion in 2011, has realigned its strategy.
